Wen Wee

11.4k total citations
123 papers, 2.0k citations indexed

About

Wen Wee is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wen Wee has authored 123 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Oncology, 36 papers in Molecular Biology and 36 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wen Wee's work include Pancreatic and Hepatic Oncology Research (48 papers), Cancer Treatment and Pharmacology (23 papers) and Cancer Genomics and Diagnostics (22 papers). Wen Wee is often cited by papers focused on Pancreatic and Hepatic Oncology Research (48 papers), Cancer Treatment and Pharmacology (23 papers) and Cancer Genomics and Diagnostics (22 papers). Wen Wee collaborates with scholars based in United States, Spain and Italy. Wen Wee's co-authors include Manuel Hidalgo, Alex A. Adjei, Grace K. Dy, Bonnie L. Hylander, Elizabeth A. Repasky, Hao Xie, Tanios Bekaii‐Saab, Wells A. Messersmith, Martín E. Fernández-Zapico and Amit Mahipal and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Wen Wee

117 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wen Wee United States	27	1.1k	742	393	385	246	123	2.0k
Viktória László Hungary	29	715 0.6×	834 1.1×	581 1.5×	372 1.0×	273 1.1×	70	2.3k
Ralph Fritsch Germany	23	678 0.6×	903 1.2×	292 0.7×	429 1.1×	285 1.2×	67	1.8k
Arne Scholz Germany	26	995 0.9×	714 1.0×	490 1.2×	319 0.8×	266 1.1×	64	1.9k
Dana T. Aftab United States	20	882 0.8×	803 1.1×	574 1.5×	417 1.1×	95 0.4×	45	1.8k
Dustin A. Deming United States	24	1.0k 0.9×	616 0.8×	327 0.8×	455 1.2×	280 1.1×	157	1.8k
Reinhard von Roemeling United States	23	728 0.6×	774 1.0×	626 1.6×	606 1.6×	212 0.9×	72	2.0k
Motohisa Tada Japan	28	1.0k 0.9×	1.3k 1.8×	295 0.8×	492 1.3×	457 1.9×	53	2.3k
Junzhong Lin China	19	629 0.6×	846 1.1×	311 0.8×	572 1.5×	294 1.2×	64	1.7k
Kevin Shee United States	16	956 0.8×	1.2k 1.6×	312 0.8×	385 1.0×	98 0.4×	56	2.0k
Thibault Mazard France	19	1.0k 0.9×	570 0.8×	400 1.0×	863 2.2×	218 0.9×	90	1.8k

Countries citing papers authored by Wen Wee

Since Specialization

Citations

This map shows the geographic impact of Wen Wee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen Wee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen Wee more than expected).

Fields of papers citing papers by Wen Wee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen Wee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen Wee. The network helps show where Wen Wee may publish in the future.

Co-authorship network of co-authors of Wen Wee

This figure shows the co-authorship network connecting the top 25 collaborators of Wen Wee. A scholar is included among the top collaborators of Wen Wee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen Wee. Wen Wee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kang, Di, Yanping Wang, Yiwei Lin, et al.. (2025). JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies. Clinical Cancer Research. 31(14). 3019–3032.

Stachowiak, Ewa K., Spencer R. Rosario, Joseph A. Spernyak, et al.. (2024). Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors. Clinical Cancer Research. 30(7). 1367–1381. 1 indexed citations

Wehrle, Chase J., Sofía Ferreira-González, Neda Dadgar, et al.. (2024). Tumor organoids for primary liver cancers: A systematic review of current applications in diagnostics, disease modeling, and drug screening. JHEP Reports. 6(12). 101164–101164. 5 indexed citations

Desai, Aakash, Daheui Choi, Þorvarður R. Hálfdánarson, et al.. (2024). Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers. 16(10). 1861–1861. 1 indexed citations

Li, Yadi, Brittany Lapin, Le H. Hua, et al.. (2024). Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors. Annals of Clinical and Translational Neurology. 12(3). 643–647.

Wehrle, Chase J., Wen Wee, Smitha Krishnamurthi, et al.. (2023). Immunotherapy Plus Locoregional Therapy Leading to Curative-Intent Hepatectomy in HCC: Proof of Concept Producing Durable Survival Benefits Detectable with Liquid Biopsy. Cancers. 15(21). 5220–5220. 11 indexed citations

Desai, Aakash, Hani M. Babiker, Mohamad Bassam Sonbol, et al.. (2023). Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience. JCO Precision Oncology. 7(7). e2200706–e2200706. 30 indexed citations

McWilliams, Robert R., Pashtoon Murtaza Kasi, Nathan R. Foster, et al.. (2023). Trial in progress: Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated metastatic pancreatic cancer.. Journal of Clinical Oncology. 41(4_suppl). TPS780–TPS780. 3 indexed citations

Choi, Daheui, Alan M. Gonzalez‐Suarez, Frank Cichocki, et al.. (2023). Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy. Advanced Science. 11(5). e2303088–e2303088. 39 indexed citations

10.

Foster, Nathan R., Yanyan Lou, Yujie Zhao, et al.. (2023). A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9093–9093. 2 indexed citations

11.

Gile, Jennifer, Fang‐Shu Ou, Amit Mahipal, et al.. (2021). FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology. 5(5). 1228–1240. 6 indexed citations

12.

Jusko, William J., et al.. (2021). Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. Journal of Pharmacology and Experimental Therapeutics. 377(3). 370–384. 5 indexed citations

13.

Bekaii‐Saab, Tanios, Þorvarður R. Hálfdánarson, Zhaohui Jin, et al.. (2020). Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer. Pancreatology. 21(2). 379–383. 7 indexed citations

14.

Wang, Jun, et al.. (2019). Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model. Molecular Cancer Therapeutics. 18(11). 2074–2084. 24 indexed citations

15.

Gabriel, Emmanuel, Kristopher Attwood, Wen Wee, et al.. (2017). Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation. Clinical Colorectal Cancer. 16(4). 300–307. 26 indexed citations

16.

Calvo, Emiliano, Jean‐Charles Soria, Wen Wee, et al.. (2016). A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical Cancer Research. 23(5). 1177–1185. 29 indexed citations

17.

Hylander, Bonnie L., et al.. (2015). Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model. Molecular Cancer Therapeutics. 15(1). 84–93. 29 indexed citations

18.

Infante, Jeffrey R., Karim A. Benhadji, Grace K. Dy, et al.. (2015). Phase 1b study of the oral gemcitabine ‘Pro-drug’ LY2334737 in combination with capecitabine in patients with advanced solid tumors. Investigational New Drugs. 33(2). 432–439. 14 indexed citations

19.

Wee, Wen, Wells A. Messersmith, Grace K. Dy, et al.. (2012). Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer. Clinical Cancer Research. 18(7). 2048–2055. 42 indexed citations

20.

Dy, Grace K., Jeffrey R. Infante, Sabine Eckhardt, et al.. (2012). Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Investigational New Drugs. 31(4). 891–899. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact